Reda Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.09 M
- Satisfied Charges ₹ 3.00 M
About Reda Pharma
Reda Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 May 2009 and has a history of 15 years and nine months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹2.09 M. The company has closed loans amounting to ₹3.00 M, as per Ministry of Corporate Affairs (MCA) records.
Waheed Shaik and Fouzia Shaik serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100TG2009PTC063593
- Company No.
063593
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 May 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Reda Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Waheed Shaik  | Managing Director | 07-May-2009 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Fouzia Shaik | Director | 01-Dec-2011 | Current |
Financial Performance of Reda Pharma.
Reda Pharma Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Reda Pharma?
In 2017, Reda Pharma had a promoter holding of 55.00% and a public holding of 45.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.09 M
₹3.00 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Mar 2023 | Hdfc Bank Limited | ₹2.09 M | Open |
| 26 Sep 2022 | Uco Bank | ₹3.00 M | Satisfied |
How Many Employees Work at Reda Pharma?
Unlock and access historical data on people associated with Reda Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reda Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reda Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
